Jewish American Heritage Month

Posted By richards on August 30, 2015

BIC (2000). Breast Cancer Information Core. Website.

Couch, F. J. et al. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20): 1409-15.

Dorum, A. et al. (1999). Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur J Cancer 35(5): 779-81.

FitzGerald, M. G. et al. (1996). Germ-line BRCA1 mutations in Jewish and non-Jewish women with early- onset breast cancer. N Engl J Med 334(3): 143-9.

Petrij-Bosch, A. et al. (1997). BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients [published erratum appears in Nat Genet 1997 Dec;17(4):503]. Nat Genet 17(3): 341-5.

Roa, B. B. et al. (1996). Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2): 185-7.

Struewing, J. P., et al. (1995). The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals [published erratum appears in Nat Genet 1996 Jan;12(1):110]. Nat Genet 11(2): 198-200.

Struewing, J. P. et al. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20): 1401-8.

Szabo, C. I. and M. C. King (1997). Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60(5): 1013-20.

Thorlacius, S. et al. (1998). Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352(9137): 1337-9.

Tonin, P. w. b. o. et al. (1996). Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast Cancer Families. Nature Medicine 2: 1179-1183.

Original post:
Breast and Ovarian Cancer in the Ashkenazi Jewish Population

Category: Ashkenazi
Tags: